Shares of RadNet Inc. (RDNT) hit a new 52-week high of $3.97 in mid-day trading on Apr 7 eventually closing at $3.76 on the same day. In fact, shares of this CA-based outpatient diagnostic imaging services provider have been gaining momentum since it reported strong fourth-quarter and full-year 2013 results on Mar 3.
Year to date, the company's shares recorded a healthy return of 132.1%. The company's long-term estimated EPS growth rate is pegged at 10%.
Strong First-Quarter Performance
RadNet posted stronger-than-expected fourth-quarter results. The company's adjusted earnings per share (excluding severance costs, loss of disposal and amortization of deferred financing fees and discount on issuance of debt) were 9 cents in the quarter, which beat the Zacks Consensus Estimate by 8 cents and increased significantly from the prior-year quarter's loss of 11 cents per share.
RadNet's fourth-quarter revenues increased 11.9% year over year to $178.3 million, beating the Zacks Consensus Estimate by 3.12%. For full-year 2013, the company's revenues were $703 million, up 8.6% from 2012.
In the fourth quarter, RadNet performed an increased number of total procedures which came in at 1,137,825, up 12.2% from the prior-year quarter; with major hikes in procedures for MRIs and routine imaging exams.
For the fourth quarter of 2013, Radnet's MRI volume increased 16.8% while CT volume increased 5% over the prior-year quarter. The company's overall volume, including x-ray, ultrasound, mammography and other exams, increased 12.2% in the quarter and 9.3% in 2013.
Sequentially, RadNet experienced significant improvement in its operating performance, primarily driven by increased revenues and procedures as well as solid expense management.
Other Stocks to Consider
RadNet currently carries a Zacks Rank #4 (Sell). Some stocks that warrant a look within the broader medical sector are Alkermes plc (ALKS), Alexion Pharmaceuticals, Inc. (ALXN) and ANI Pharmaceuticals, Inc. (ANIP). All these stocks carry a Zacks Rank #1 (Strong Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment